---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-310408"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2021-10-28T23:59:59+00:00"
generated_at: "2026-06-28T17:04:07.970249+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Repligen Q3 revenue $178.2M (+89% YoY); raises FY 2021 revenue guidance to $655-665M

## Summary
- Revenue hit a record $178.2M in Q3 2021, up 89% YoY as reported and 77% organically.
- GAAP EPS of $0.58, Adjusted EPS of $0.78; GAAP operating margin rose to 25.4%.
- FY 2021 revenue guidance raised to $655-665M (prior $625-645M); adjusted EPS guidance raised to $2.86-$2.91.
- Completed acquisition of affinity ligands innovator Avitide Inc. during the quarter.
- COVID programs contributed 27% of Q3 revenue; base business grew 49% YoY.

## SEC filing metadata
- accession: 0001193125-21-310408
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2021-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312521310408/0001193125-21-310408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312521310408/d83679d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-310408
- JSON: https://secwatch.observer/filing/0001193125-21-310408.json
- Plain text: https://secwatch.observer/filing/0001193125-21-310408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.